Managing the teratogenic risk of thalidomide and lenalidomide: an industry perspective.
Celgene has developed and operated pregnancy prevention programs since 1998 with the first approval of thalidomide in the US. With the development and marketing of lenalidomide, an analog of thalidomide, the company further advanced its risk management activities, which now cover several territories across the globe. To date, the program is a success in as much as it has minimized the risk of fetal exposure and subsequent development of fetal malformations. Nonetheless, the company understands the need to provide a mechanism for intervention and remediation when at-risk behaviors are identified, and this forms an integral part of the risk management processes. The implementation of the thalidomide and lenalidomide pregnancy prevention program partners patients, healthcare professionals, regulators and the company in a spirit of shared responsibility. This paper also presents the authors' experience and perspective on the challenges of managing a pregnancy prevention program, which at its core aims at ensuring that the product's benefits outweigh the risk of fetal exposure.
Robert
R
Bwire
John
J
Freeman
Florence
F
Houn
D000014:Abnormalities, Drug-Induced / Q000209:etiology* / Q000517:prevention & control*; D003267:Contraception / Q000379:methods; D000075202:Contraindications; D004345:Drug Industry / Q000379:methods*; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D011247:Pregnancy; D012308:Risk Management; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives*
D013792:Thalidomide; D000077269:Lenalidomide